NEW YORK (WKZO) -- It could be the next big drug in the pipeline for Pfizer, a multi-billion dollar seller that appears in initial testing to be a ground-breaking drug for the treatment of advanced breast cancer.
Dr. David Agus at the Westside Cancer Center says clinical trials show it can double the time patients lived without the cancer getting worse.
He would like to see Phizer apply to the FDA for early release of the drug, because it may be to useful to hold back from patients who have few other alternatives.
He says they suspect it may have the same effect on other cancers.
Analysts are predicting that the drug could be earning three billion a year for Pfizer by 2020.